Eye­ing quick ap­proval, Ab­b­Vie of­fers a close-up on their pres­by­opia drug da­ta

Ab­b­Vie picked up some bonus points ear­li­er this year as one of its pipeline adds from the $63 bil­lion Al­ler­gan buy­out hit its top-line marks. And now the re­searchers have pro­duced the de­tailed da­ta on the case they are mak­ing with reg­u­la­tors, with an eye on a ma­jor new mar­ket and a hoped-for ap­proval be­fore New Year’s.

AGN-190584 is aim­ing to be the first easy-on eye­drop for pres­by­opia, a com­mon ail­ment for large num­bers of peo­ple who find it hard­er and hard­er to read things like a watch or cell phone close up. Any­one who’s held a book out at arm’s length in or­der to read it will be very fa­mil­iar with the con­di­tion, if not the ex­act di­ag­no­sis.

Their Phase III study — Gem­i­ni I — came up with some con­vinc­ing proof that the eye­drops de­liv­er fast though tran­sient im­prove­ments in read­ing abil­i­ty, with a sta­tis­ti­cal­ly sig­nif­i­cant group of pa­tients adding 3 lines or more when view­ing a read­ing chart.

Ab­b­Vie’s team turned up at the 2021 Amer­i­can So­ci­ety of Cataract and Re­frac­tive Surgery an­nu­al meet­ing to show­case the da­ta, which in­cludes a gen­er­al­ly clean bill of health on safe­ty.

“While not of­ten known by name, the 128 mil­lion Amer­i­cans liv­ing with pres­by­opia feel the con­di­tion’s im­pact through­out their dai­ly lives, of­ten when look­ing at their cell phones, read­ing or try­ing to see a menu in a dim­ly lit restau­rant. Ad­di­tion­al­ly, our ever-in­creas­ing time spent on dig­i­tal de­vices, from smart­watch­es to smart­phones, has put un­prece­dent­ed de­mands on our vi­sion,” said George O. War­ing IV, the GEM­I­NI prin­ci­pal study in­ves­ti­ga­tor.

Here’s a break­out:

The pri­ma­ry and key sec­ondary end­points were met with a sta­tis­ti­cal­ly sig­nif­i­cant greater pro­por­tion of par­tic­i­pants treat­ed with AGN-190584 who gained three lines or more (the abil­i­ty to read three ad­di­tion­al lines on a read­ing chart) in mesopic (in low light), high con­trast, binoc­u­lar Dis­tance Cor­rect­ed Near Vi­su­al Acu­ity (DC­N­VA) at Day 30, Hour 3 (22.5%, p < 0.0001) and Hour 6 (9.7%, p = 0.0114) ver­sus the ve­hi­cle. The re­sults demon­strat­ed AGN-190584 had a rapid on­set of 15 min­utes and du­ra­tion of up to six hours in mesopic DC­N­VA with­out loss of dis­tance vi­sion af­ter ad­min­is­tra­tion at Day 30. Ad­di­tion­al end­points eval­u­at­ed showed that 75% of par­tic­i­pants treat­ed with AGN-190584 achieved a ≥2-line im­prove­ment in mesopic DC­N­VA; and 93% of par­tic­i­pants achieved ≥20/40 vi­sion in pho­topic (day­light) DC­N­VA. Im­prove­ments were al­so ob­served in Dis­tance Cor­rect­ed In­ter­me­di­ate Vi­su­al Acu­ity (DCI­VA) for up to 10 hours at Day 30.

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

Geoffrey Porges, new Schrödinger CFO

Long­time an­a­lyst Ge­of­frey Porges de­parts SVB to lead fi­nances at a drug dis­cov­ery shop

Geoffrey Porges has ended his two-decade run as a biotech analyst, as the former SVB Securities vice chair began as CFO of Schrödinger on Thursday.

The long-running analyst, who previously headed up vaccines marketing at Merck before the turn of the millennium, will lead the financial operations of the 700-employee company as Schrödinger broadens its focus from a drug discovery partner to also building out an in-house pipeline, with clinical trial No. 1 set to begin next quarter.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

FDA ap­proves one of the prici­est new treat­ments of all time — blue­bird's gene ther­a­py for be­ta tha­lassemia

The FDA on Wednesday approved the first gene therapy for a chronic condition — bluebird bio’s new Zynteglo (beti-cel) as a potentially curative treatment for those with transfusion-dependent thalassemia.

The thumbs-up from the FDA follows a unanimous adcomm vote in June, with outside experts pointing to extraordinary efficacy, with 89% of subjects with TDT who received beti-cel having achieved transfusion independence.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

Kate Haviland, Blueprint Medicines CEO

Blue­print met all its end­points in bid for ex­pand­ed Ay­vak­it la­bel — but stock trends low­er any­way

Blueprint Medicines announced this morning that the second part of its study on Ayvakit in non-advanced systemic mastocytosis (SM) — a rare disease in which a type of white blood cells known as mast cells builds up — met all endpoints, but the biopharma left key questions unanswered.

In 212 patients, with 141 in the treatment arm and 71 in the control arm, patients who got Ayvakit saw an average 15.6-point decrease in their symptom scores compared to a 9.2-point decrease in the placebo arm at 24 weeks. In an extension study, those on Ayvakit saw their symptom scores drop by 20.2 points by week 48.

James Sabry, Roche global head of pharma partnering

Roche, Genen­tech plunk down $60M up­front to part­ner with Chi­nese phar­ma on PRO­TAC-based prostate can­cer drug

Roche and Genentech are always on the hunt for deals, and on Thursday they found their newest partner.

The pair will team up with the Chinese pharma company Jemincare to push forward a new program for prostate cancer, the companies announced. Roche is ponying up $60 million upfront to get its hands on the candidate and promising up to $590 million in biobucks, plus royalties, down the line.

In return, Genentech will get a worldwide license to develop the program, known as JMKX002992, and bring it to market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

Andrew Hopkins, Exscientia CEO

Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

Bayer and Exscientia are winding down their three-year collaboration, leaving the big German pharma to take the AI-designed compounds born out of the pact further.

London-based Exscientia revealed in its Q2 update that the partners have “mutually agreed to end” their collaboration, which kicked off in early 2020, after recently achieving a drug discovery milestone. In an SEC filing, Exscientia said it terminated the pact on May 30, about six months early.

Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Sanofi is officially giving up on its oral SERD.

The French drugmaker put out word Wednesday morning that it will discontinue the global development program of amcenestrant, the selective estrogen receptor degrader once billed as a top late-stage prospect. Having already failed a Phase II monotherapy test earlier this year, a combo with the drug also missed the bar in a second trial for breast cancer, triggering the decision to drop the whole program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

Bayer's first DTC ad campaign for chronic kidney disease drug Kerendia spells out its benefits

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

Do you know the ABCs of CKD in T2D? Bayer’s first ad campaign for Kerendia tackles the complexity of chronic kidney disease with a play on the acronym (CKD) and its connection to type 2 diabetes (T2D).

Kerendia was approved last year as the first and only non-steroidal mineralocorticoid receptor antagonist to treat CKD in people with type 2 diabetes.

In the TV commercial launched this week, A is for awareness, B is for belief and C is for cardiovascular, explained in the ad as awareness of the connection between type 2 and kidney disease, belief that something can be done about it, and cardiovascular events that may be reduced with treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

James Mock, incoming CFO at Moderna

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

When Moderna hired a new CFO last year,  it didn’t expect to see him gone after only one day. Today the biotech named his — likely much more vetted — replacement.

The mRNA company put out word early Wednesday that after the untimely departure of then brand-new CFO Jorge Gomez, it has now found a replacement in James Mock, the soon-to-be former CFO at diagnostics and analytics company PerkinElmer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.